A previous meta-analysis which analysed 30 studies with the total of 2986 patients demonstrated MGMT methylation status as a prognostic factor in GBM patients showing significant association with better OS and progression free survival (PFS) for patient treatment with alkylating agents [5]. This evidence concerns the gene MGMT and glioblastoma.